Travere Therapeutics (TVTX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $14.47 to $14.87
• 50-Day Range: $13.49 to $23.75
• 52-Week Range: $5.12 to $25.29
• Volume: 19,324 shs
• Average Volume: 1.51 million shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.08
• Consensus Rating: Moderate Buy

Travere Therapeutics Stock Analysis - MarketRank™

Travere Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 577th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Travere Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Travere Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Travere Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Travere Therapeutics has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.39% of the float of Travere Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Travere Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Travere Therapeutics has recently increased by 3.31%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Travere Therapeutics does not currently pay a dividend.

Dividend Growth

Travere Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.39% of the float of Travere Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Travere Therapeutics has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Travere Therapeutics has recently increased by 3.31%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.91

News Sentiment

Travere Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Travere Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,147,627.00 in company stock.

Percentage Held by Insiders

Only 3.75% of the stock of Travere Therapeutics is held by insiders.

TVTX Stock Analysis - Frequently Asked Questions

How have TVTX shares performed this year?

Travere Therapeutics' stock was trading at $17.42 on January 1st, 2025. Since then, TVTX shares have decreased by 17.7% and is now trading at $14.3450.
View the best growth stocks for 2025 here.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its quarterly earnings results on Thursday, February, 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.15. The business earned $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative trailing twelve-month return on equity of 1,636.87%.
Read the conference call transcript.

Who are Travere Therapeutics' major shareholders?

Top institutional investors of Travere Therapeutics include Assenagon Asset Management S.A. (0.47%), Rhumbline Advisers (0.14%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Eric M Dube, Steve Aselage, Peter Heerma, William E Rote, Christopher R Cline, Jula Inrig, Jeffrey A Meckler, Elizabeth E Reed, Sandra Calvin, Gary A Lyons, Laura Clague and Roy D Baynes.
View institutional ownership trends.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 4/16/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVTX
• CIK: 1438533
• Web: www.retrophin.com
• Phone: (888) 969-7879
• Fax: 302-645-1280
• Employees: 460
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.08
• High Stock Price Target: $47.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +115.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-111,400,000.00
• Net Margins: -137.90%
• Pretax Margin: -171.40%
• Return on Equity: -1,636.87%
• Return on Assets: -55.95%

Debt

• Debt-to-Equity Ratio: 24.96
• Current Ratio: 1.71
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: $233.18 million
• Price / Sales: 5.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 5.58

Miscellaneous

• Outstanding Shares: 88,772,000
• Free Float: 75,123,000
• Market Cap: $1.32 billion
• Optionable: Optionable
• Beta: 0.84